Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Vorinostat for Advanced Cutaneous T-Cell Lymphoma
2006-003879-12Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vorinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Merck & Co. Primary endpoints: Physician-assessed response rate, Safety and tolerability and 1 more. Started Jan 2007; status: completed.
02
Drugs
vorinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2006-003879-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003879-12.